Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
Systemic Lupus Erythematosus
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
Telitacicept Fast-Tracked for Systemic Lupus Erythematosus
The FDA has granted Fast Track designation to telitacicept (RC18; RemeGen) for the treatment of systemic lupus erythematosus.
Doctors, Hospitals, Pharmacies Warned Not to Stockpile Meds
Professional societies issue stern warning not to inappropriately prescribe meds for COVID-19.
Anifrolumab Improves Response at 52 Weeks in Lupus
Rate of composite response showing reduced disease activity higher with anifrolumab versus placebo
Glucocorticoid Use Associated With Increased Risk for Cardiovascular Disease in SLE
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Diagnoses of RA, SLE Linked to Increased Opioid Overdose Hospitalization Risk
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
High Doses of Hydroxychloroquine May Protect Against Thrombosis in SLE
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
Anifrolumab Effectively Reduced Disease Activity for Lupus Patients in Phase 3 Trial
AstraZeneca has announced positive topline data from the phase 3 TULIP 2 trial of anifrolumab for the treatment of systemic lupus erythematosus (SLE). Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor and blocking all type I IFNs including IFN-alpha, IFN-beta and IFN-omega. The TULIP…
Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
